About von Willebrand factor C domain-containing protein 2-like
von Willebrand factor C domain-containing protein 2-like (VWC2L) is a protein
from Homo sapiens identified by UniProt accession
B2RUY7, 222 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | von Willebrand factor C domain-containing protein 2-like |
|---|
| UniProt accession | B2RUY7 |
|---|
| Gene | VWC2L |
|---|
| Organism | Homo sapiens |
|---|
| Length | 222 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (34)
Diseases linked to this target (Open Targets).
- self reported educational attainment · score 0.44
- mathematical ability · score 0.40
- neuroticism measurement · score 0.39
- insomnia measurement · score 0.38
- wellbeing measurement · score 0.37
- feeling "fed-up" measurement · score 0.35
- depressive symptom measurement · score 0.32
- schizophrenia · score 0.32
- cognitive function measurement · score 0.31
- alcohol consumption measurement · score 0.31
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-B2RUY7-F1 | alphafold | PREDICTED | 77.77 | — |
Amino-acid sequence (222 residues)
MALHIHEACI LLLVIPGLVT SAAISHEDYP ADEGDQISSN DNLIFDDYRG KGCVDDSGFV YKLGERFFPG HSNCPCVCAL DGPVCDQPEC PKIHPKCTKV EHNGCCPECK EVKNFCEYHG KNYKILEEFK PSPCEWCRCE PSNEVHCVVA DCAVPECVNP VYEPEQCCPV CKNGPNCFAG TTIIPAGIEV KVDECNICHC HNGDWWKPAQ CSKRECQGKQ TV
Explore von Willebrand factor C domain-containing protein 2-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets